2025/10/28
Shanghai, October 28, 2025 – WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced it has signed two strategic memoranda of understanding (MoUs) with NEOM, the sustainable region under development in northwest Saudi Arabia and the Ministry of Health of the Kingdom of Saudi Arabia (MOH).
Read more2025/10/26
WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, and Hillhouse Investment Management (“Hillhouse”), one of the world’s leading global private alternative asset managers, announced that they have reached an agreement for Hillhouse to acquire WuXi AppTec’s China-based clinical research services business, including WuXi Clinical, a Clinical Contract Research Organization (CRO), and WuXi MedKey, a Site Management Organization (SMO)
Read more2025/10/26
(SHANGHAI, October 26, 2025) – WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced financial results for the first three quarters ending September 30, 2025 (“Reporting Period”):
Read more2025/10/26
WuXi AppTec Unveils Modernized Logo, Reflecting Continued Evolution as a Global Healthcare Partner
Read more2025/09/21
Shanghai, September 21, 2025 – WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, implemented its first interim dividend plan, distributing a total of RMB1.03 billion in cash dividends.
Read more